Axonics Expects Q4 FY23 Revenues Of $109.3M-$109.7M, Up 27% Y/Y Versus Consensus Of $105.56M
Portfolio Pulse from Benzinga Newsdesk
Axonics anticipates Q4 FY23 revenues to range between $109.3M and $109.7M, marking a 27% year-over-year increase, surpassing the consensus estimate of $105.56M. Sacral neuromodulation revenue is expected to rise by 26% to $88.3M-$88.5M, while Bulkamid revenue is projected to grow by 35% to $21.0M-$21.2M.
January 08, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axonics expects Q4 FY23 revenues to surpass expectations with a 27% Y/Y increase, driven by growth in sacral neuromodulation and Bulkamid sales.
The positive revenue forecast for Axonics, which exceeds analyst consensus, is likely to instill investor confidence and could lead to a short-term increase in stock price. The significant growth in sacral neuromodulation and Bulkamid sales, both key product areas, further reinforces the positive outlook for the company.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100